tolmar

Educational Programs Designed
for Pediatric Endocrinologists


The Central Precocious Puberty (CPP) Journey

Tolmar is committed to providing **educational programs** tailored to the needs of healthcare professionals in your practice—available both virtually and in-person.

This series of programs will explore the patient and caregiver treatment journey through CPP, offering valuable insights to enhance patient care and clinical outcomes.



MODULE 1




Whom to Treat

OBJECTIVES

- Discuss epidemiology, etiology, and clinical presentation of CPP
- Review potential physical and psychosocial effects of CPP
- Describe diagnostic evaluation of CPP
- Identify candidates for GnRH (gonadotropin-releasing hormone) agonist therapy based on clinical presentation, chronological age, and the results of diagnostic testing

MODULE 2



How to Treat

OBJECTIVES

- Describe the role of GnRH agonist therapy in the management of CPP
- Review treatment options for CPP, including routes of administration and dosing schedules
- Discuss recommendations for monitoring during GnRH agonist therapy for CPP

To schedule a program or learn more, email us at **events@tolmar.com**

CONTINUED

The Central Precocious Puberty (CPP) Journey

Educational Programs Designed for Pediatric Endocrinologists

MODULE 3




When to Discontinue GnRH Agonist Treatment

OBJECTIVES

- Identify children with CPP who may benefit from ongoing treatment with GnRH agonist therapy
- Review strategies to individualize discussions related to discontinuation of GnRH agonist therapy for CPP

MODULE 4



Expert Perspectives:

GnRHa Treatment Long-term Implications for Children with CPP

OBJECTIVES

- GnRHa treatment long-term implications for height in children with CPP
- GnRHa treatment long-term implications for bone density, menses, and fertility in children with CPP

Schedule a Virtual or In-person Program

email us at **events@tolmar.com**

© 2025 Tolmar, Inc. All rights reserved. Tolmar and its associated logo are trademarks of the Tolmar group. Third party trademarks and product names belong to their respective owners. TPI.2025.eng.5171.v1 10/25

tolmar